| 29.355 0 (0%) | 08-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.28 | 1-year : | 40.04 |
| Resists | First : | 29.35 | Second : | 34.28 |
| Pivot price | 29.35 | |||
| Supports | First : | 29.35 | Second : | 29.35 |
| MAs | MA(5) : | 29.35 | MA(20) : | 29.35 |
| MA(100) : | 29.35 | MA(250) : | 0 | |
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 78.4 | |||
| 52-week | High : | 31.7 | Low : | 5.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MCTA ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 29.42 - 29.57 | 29.57 - 29.69 |
| Low: | 28.94 - 29.15 | 29.15 - 29.31 |
| Close: | 29.08 - 29.38 | 29.38 - 29.62 |
Operating through its subsidiaries and under the Beauty Lab brand in Hong Kong, Charming Medical Limited delivers a comprehensive suite of beauty, wellness, and postpartum services. These services encompass womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox, agarwood moxibustion, TCM-inspired prenatal massages, and Indonesian traditional abdominal binding. In addition to these treatments, the company manufactures and distributes various products. Their product line features TCM-inspired supplements, including the Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets. They also offer beauty products like a ginseng soothing anti-allergy moisturizing wash for various skin issues and solutions for scalp health. The company further provides consultancy services, offering technical training in TCM-inspired therapies and dietary guidance to other well-regarded beauty salons, massage centers, and similar institutions. These services and products are specifically formulated to alleviate premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal symptoms, and concerns related to breast and uterine health. They also contribute to enhancing overall physical strength and balancing endocrine functions, addressing a wide array of common women's health challenges. Charming Medical operates its own network of wellness centers. Founded in 2016, the company maintains its headquarters in Causeway Bay, Hong Kong.
Tue, 25 Aug 2026
Charming Medical Lawsuit: MCTA Defendants Seek Dismissal of Investor Securities Claims - TipRanks
Tue, 21 Oct 2025
symbol__ Stock Quote Price and Forecast - CNN
Tue, 21 Oct 2025
Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq - The Manila Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 15 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 68.1 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 575 (K) |
| Shares Short P.Month | 576 (K) |
| EPS | 0.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | -0.5 % |
| Operating Margin | 4.8 % |
| Return on Assets (ttm) | 0.8 % |
| Return on Equity (ttm) | -0.9 % |
| Qtrly Rev. Growth | -18.9 % |
| Gross Profit (p.s.) | 0.3 |
| Sales Per Share | 0.31 |
| EBITDA (p.s.) | 0.02 |
| Qtrly Earnings Growth | -93.9 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | 419.35 |
| PEG Ratio | 0 |
| Price to Book value | 97.84 |
| Price to Sales | 92.64 |
| Price to Cash Flow | -365.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|